Phase III, multicenter, randomized, open-label study to evaluate the efficacy and safety of adjuvant giredestrant compared to physician-selected adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer. LEAD
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: F. HOFFMANN-LA ROCHE LTD
- Phase: III
- Execution start: 25/02/2022
- End of execution: 30/03/2034
- IP: ISABEL BLANCAS LOPEZ-BARAJAS